NAV

Angiotensin 1-7

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Angiotensin 1-7
Accession Number
DB11720
Description

TXA127 has been investigated for the treatment of Miscellaneous Peripheral Blood Cell Abnormalities.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Similar Structures
Weight
Average: 899.02
Monoisotopic: 898.466100864
Chemical Formula
C41H62N12O11
Synonyms
  • Angiotensin (1-7)
  • Angiotensin I (1-7)
  • Angiotensin II (1-7) heptapeptide
External IDs
  • TXA-127
  • TXA127

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Unlock Additional Data
AcebutololAcebutolol may increase the hypotensive activities of Angiotensin 1-7.
AceclofenacThe therapeutic efficacy of Angiotensin 1-7 can be decreased when used in combination with Aceclofenac.
AcemetacinThe therapeutic efficacy of Angiotensin 1-7 can be decreased when used in combination with Acemetacin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Angiotensin 1-7.
AlclofenacThe therapeutic efficacy of Angiotensin 1-7 can be decreased when used in combination with Alclofenac.
AldesleukinAldesleukin may increase the hypotensive activities of Angiotensin 1-7.
AlfentanilAlfentanil may decrease the antihypertensive activities of Angiotensin 1-7.
AlfuzosinAlfuzosin may increase the hypotensive activities of Angiotensin 1-7.
AliskirenAliskiren may increase the hypotensive activities of Angiotensin 1-7.
AlmotriptanAlmotriptan may decrease the antihypertensive activities of Angiotensin 1-7.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Peptides
Alternative Parents
Histidine and derivatives / Proline and derivatives / N-acyl-L-alpha-amino acids / Alpha amino acid amides / Beta amino acids and derivatives / Amphetamines and derivatives / Pyrrolidine carboxylic acids / Imidazolyl carboxylic acids and derivatives / N-acylpyrrolidines / 1-hydroxy-2-unsubstituted benzenoids
show 16 more
Substituents
1-hydroxy-2-unsubstituted benzenoid / Alpha peptide / Alpha-amino acid amide / Alpha-amino acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Amphetamine or derivatives / Aromatic heteromonocyclic compound / Azacycle
show 39 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
angiotensin (CHEBI:55438)

Chemical Identifiers

UNII
IJ3FUK8MOF
CAS number
51833-78-4
InChI Key
PVHLMTREZMEJCG-GDTLVBQBSA-N
InChI
InChI=1S/C41H62N12O11/c1-5-22(4)33(38(61)50-29(17-24-19-45-20-47-24)39(62)53-15-7-9-30(53)40(63)64)52-36(59)28(16-23-10-12-25(54)13-11-23)49-37(60)32(21(2)3)51-35(58)27(8-6-14-46-41(43)44)48-34(57)26(42)18-31(55)56/h10-13,19-22,26-30,32-33,54H,5-9,14-18,42H2,1-4H3,(H,45,47)(H,48,57)(H,49,60)(H,50,61)(H,51,58)(H,52,59)(H,55,56)(H,63,64)(H4,43,44,46)/t22-,26-,27-,28-,29-,30-,32-,33-/m0/s1
IUPAC Name
(2S)-1-[(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]-3-methylpentanamido]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid
SMILES
[H][C@](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCC[C@H]1C(O)=O

References

General References
Not Available
PubChem Compound
123805
PubChem Substance
347828083
ChemSpider
110354
BindingDB
85556
ChEBI
55438
ChEMBL
CHEMBL3545347
ZINC
ZINC000096077632

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedSupportive CareAnemia / Lymphopenia / Neutropenia / Thrombocytopenia1
2CompletedTreatmentBone Cancer / Chondrosarcomas / Clear Cell Sarcoma of the Kidney / Metastatic Bone Sarcomas / Ovarian Sarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Osteosarcoma / Recurrent Uterine Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage III Uterine Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Stage IV Uterine Sarcoma1
2Not Yet RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
2RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
2TerminatedSupportive CareHodgkins Disease (HD) / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2WithdrawnSupportive CareMalignancies, Hematologic2
2WithdrawnTreatmentCord Blood Transplant / Inherited Metabolic Diseases / Malignancies, Hematologic1
2, 3Not Yet RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere / Infections, Coronavirus / Respiratory Failure1
1CompletedTreatmentMiscellaneous Peripheral Blood Cell Abnormalities1
1RecruitingOtherBMI >30 kg/m2 / High Blood Pressure (Hypertension) / Insulin Resistance / Metabolic Cardiovascular Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0399 mg/mLALOGPS
logP-1.4ALOGPS
logP-6.3ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)2.95ChemAxon
pKa (Strongest Basic)11.74ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count16ChemAxon
Hydrogen Donor Count13ChemAxon
Polar Surface Area377.24 Å2ChemAxon
Rotatable Bond Count25ChemAxon
Refractivity238.19 m3·mol-1ChemAxon
Polarizability92.45 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 14:42 / Updated on June 12, 2020 10:53

124